Biomarker & Intervention Discovery

Breast Cancer

This page lists 13 druggable gene targets, 44 approved or trial-tested drug candidates and 15 recent clinical trials for Breast Cancer, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Breast Cancer (2026): Drugs in Trials

US DALYs1.37MWHO GHE 2021 · all ages
Global DALYs22.85MWHO GHE 2021 · worldwide
US mortality48.9K deaths/yrWHO GHE 2021
Global mortality701.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$757MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionSpontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving…
Best-intervention remissionHER2+ metastatic: pertuzumab + trastuzumab + docetaxel (CLEOPATRA: 57.1-month median OS vs 40.8 months); HR+/HER2-…
Gap sizeVaries greatly by subtype; HER2+ and HR+ have dramatically improved outcomes; TNBC lags; metastatic remains incurable…
Primary barrierbiological (metastatic) + access (treatment disparities by race/SES)
Full remission profile →
Research Tracker Chronic Disease Interventions Breast Cancer

Remission & chronicity

Spontaneous remission
Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy
Best-intervention remission
HER2+ metastatic: pertuzumab + trastuzumab + docetaxel (CLEOPATRA: 57.1-month median OS vs 40.8 months); HR+/HER2- with CDK4/6 inhibitors: 63-month PFS in first-line (MONALEESA-2); TNBC with pembrolizumab + chemotherapy: 23-month OS vs 16.1 months; pCR with neoadjuvant: 80-90% in HER2+ with dual HER2 blockade
Gap size
Varies greatly by subtype; HER2+ and HR+ have dramatically improved outcomes; TNBC lags; metastatic remains incurable in most patients
Primary barrier
biological (metastatic) + access (treatment disparities by race/SES)
Racial disparities in breast cancer mortality persist (Black women 40% higher mortality despite similar incidence); access to genetic testing (BRCA1/2) and CDK4/6 inhibitors varies significantly; germline testing vastly underutilised

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

AKT1 248AR 994BRCA1 283BRCA2 19CDK4 255CDK6 226ERBB2 336ESR1 386PARP1 207PGR 158PIK3CA 444TACSTD2 4TOP2A 289

AKT1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FASUDIL ? unclear Mechanistic DGIdb
TOPOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
5-METHOXYCANTHINONE ? unclear Mechanistic DGIdb
IPATASERTIB ↓ inhibits Mechanistic DGIdb
MS15 ↓ inhibits Mechanistic DGIdb
NELFINAVIR ↓ inhibits Mechanistic DGIdb
XL418 ? unclear Mechanistic DGIdb
ENZASTAURIN ? unclear Mechanistic DGIdb
TRICIRIBINE ↓ inhibits Mechanistic DGIdb
PERIFOSINE ↓ inhibits Mechanistic DGIdb
M-2698 ↓ inhibits Mechanistic DGIdb
UPROSERTIB ↓ inhibits Mechanistic DGIdb
CANTHIN-6-ONE ? unclear Mechanistic DGIdb
CAPIVASERTIB ↓ inhibits Mechanistic DGIdb
CI-1040 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL480356 ? unclear Mechanistic DGIdb
ANDROGRAPHOLIDE ? unclear Mechanistic DGIdb
SR-13668 ↓ inhibits Mechanistic DGIdb
LAUROGUADINE ? unclear Mechanistic DGIdb
DABRAFENIB ? unclear Mechanistic DGIdb
GEFITINIB ? unclear Mechanistic DGIdb
EVEROLIMUS ↓ inhibits Mechanistic DGIdb
GIGANTOL ? unclear Mechanistic DGIdb
GSK690693 ↓ inhibits Mechanistic DGIdb
VAD-044 ~ modulates Mechanistic DGIdb
HU7691 ↓ inhibits Mechanistic DGIdb
LY-2780301 ↓ inhibits Mechanistic DGIdb
GAMBOGIC AMIDE ? unclear Mechanistic DGIdb
MIRANSERTIB ? unclear Mechanistic DGIdb
GEDATOLISIB ? unclear Mechanistic DGIdb
EUPALININ A ? unclear Mechanistic DGIdb
NINTEDANIB ESYLATE ? unclear Mechanistic DGIdb
GSK269962A ? unclear Mechanistic DGIdb
ERLOTINIB ? unclear Mechanistic DGIdb
CEP-11981 ? unclear Mechanistic DGIdb
OMIPALISIB ↓ inhibits Mechanistic DGIdb
A-674563 ↓ inhibits Mechanistic DGIdb
ARCHEXIN ? unclear Mechanistic DGIdb
CANERTINIB DIHYDROCHLORIDE ? unclear Mechanistic DGIdb
BARDOXOLONE METHYL ? unclear Mechanistic DGIdb

Showing top 40 of 248 agents ranked by evidence tier.

AR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AMI-1 ? unclear Mechanistic DGIdb
DIBEKACIN ? unclear Mechanistic DGIdb
CARBONYL CYANIDE M-CHLOROPHENYLHYDRAZONE ? unclear Mechanistic DGIdb
TRIPARANOL ? unclear Mechanistic DGIdb
DODINE ? unclear Mechanistic DGIdb
TANNIC ACID ? unclear Mechanistic DGIdb
DEFLAZACORT ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1235854 ? unclear Mechanistic DGIdb
ERGONOVINE ? unclear Mechanistic DGIdb
AMPEROZIDE HYDROCHLORIDE ? unclear Mechanistic DGIdb
ATROPINE METHYLBROMIDE ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
BERBERINE CHLORIDE ? unclear Mechanistic DGIdb
NITRALIN ? unclear Mechanistic DGIdb
DEVAZEPIDE ? unclear Mechanistic DGIdb
MOCLOBEMIDE ? unclear Mechanistic DGIdb
GLPG0492 ~ modulates Mechanistic DGIdb
DEUTENZALUTAMIDE ↓ inhibits Mechanistic DGIdb
PRUXELUTAMIDE ↓ inhibits Mechanistic DGIdb
HEPTANE ? unclear Mechanistic DGIdb
THONZONIUM BROMIDE ? unclear Mechanistic DGIdb
FENHEXAMID ? unclear Mechanistic DGIdb
LEMILDIPINE ? unclear Mechanistic DGIdb
(R)-BICALUTAMIDE ? unclear Mechanistic DGIdb
MORICIZINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
METIPRANOLOL ? unclear Mechanistic DGIdb
FLUROCHLORIDONE ? unclear Mechanistic DGIdb
PYRIDOSTIGMINE BROMIDE ? unclear Mechanistic DGIdb
FLUTAMIDE ↓ inhibits Mechanistic 154.0 nM (IC50) DGIdb
CHEMBL:CHEMBL224318 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL423081 ? unclear Mechanistic DGIdb
PREDNISOLONE ? unclear Mechanistic 2760.0 nM (Ki) DGIdb
ORBIFLOXACIN ? unclear Mechanistic DGIdb
PROGESTERONE ? unclear Mechanistic 8.5 nM (Ki) DGIdb
FLUDIOXONIL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1784521 ? unclear Mechanistic DGIdb
FLUMETHASONE ? unclear Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
MELOXICAM ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL44011 ? unclear Mechanistic DGIdb

Showing top 40 of 994 agents ranked by evidence tier.

BRCA1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
7-HYDROXY ISOFLAVONE ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
PLATINUM COMPOUND ? unclear Mechanistic DGIdb
DAIDZIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL581929 ? unclear Mechanistic DGIdb
PIDNARULEX ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1481721 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL484663 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1214407 ? unclear Mechanistic DGIdb
2-PHENYLQUINOLINE ? unclear Mechanistic DGIdb
HARMALOL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1574420 ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
MITOMYCIN ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
RESVERATROL ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL12658 ? unclear Mechanistic DGIdb
ONONIN ? unclear Mechanistic DGIdb
CEDIRANIB ? unclear Mechanistic DGIdb
PIPERINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL446567 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL546649 ? unclear Mechanistic DGIdb
DEPHOSTATIN ? unclear Mechanistic DGIdb
SEMUSTINE ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1404865 ? unclear Mechanistic DGIdb
QUARFLOXIN ? unclear Mechanistic DGIdb
PARP/TANKYRASE INHIBITOR 2X-121 ? unclear Mechanistic DGIdb
WISTIN ? unclear Mechanistic DGIdb
CHRYSIN DIMETHYL ETHER ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL600315 ? unclear Mechanistic DGIdb
AURINTRICARBOXYLIC ACID ? unclear Mechanistic DGIdb
MITOXANTRONE HYDROCHLORIDE ? unclear Mechanistic DGIdb
SACITUZUMAB GOVITECAN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL588683 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL593254 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL588525 ? unclear Mechanistic DGIdb
PURPURIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL316796 ? unclear Mechanistic DGIdb

Showing top 40 of 283 agents ranked by evidence tier.

BRCA2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARBOPLATIN ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
TALAZOPARIB ? unclear Mechanistic DGIdb
NIRAPARIB ? unclear Mechanistic DGIdb
RUCAPARIB ? unclear Mechanistic DGIdb
QUARFLOXIN ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
VELIPARIB ? unclear Mechanistic DGIdb
BOSUTINIB ? unclear Mechanistic DGIdb
PLATINUM COMPOUND ? unclear Mechanistic DGIdb
TEMOZOLOMIDE ? unclear Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
PIDNARULEX ? unclear Mechanistic DGIdb
SACITUZUMAB GOVITECAN ? unclear Mechanistic DGIdb
CEDIRANIB ? unclear Mechanistic DGIdb
INIPARIB ? unclear Mechanistic DGIdb
PARP/TANKYRASE INHIBITOR 2X-121 ? unclear Mechanistic DGIdb

CDK4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ABEMACICLIB ↓ inhibits Mechanistic DGIdb
TRILACICLIB ↓ inhibits Mechanistic DGIdb
CDK2 INHIBITOR IV ↓ inhibits Mechanistic DGIdb
VORUCICLIB ↓ inhibits Mechanistic DGIdb
LEROCICLIB ↓ inhibits Mechanistic DGIdb
RIVICICLIB ↓ inhibits Mechanistic DGIdb
CDK INHIBITOR 4.35 ↓ inhibits Mechanistic DGIdb
AZD5438 ↓ inhibits Mechanistic DGIdb
RIBOCICLIB SUCCINATE ? unclear Mechanistic DGIdb
ALPELISIB ? unclear Mechanistic DGIdb
ALVOCIDIB ↓ inhibits Mechanistic DGIdb
CDK4 INHIBITOR III ↓ inhibits Mechanistic DGIdb
PURVALANOL B ↓ inhibits Mechanistic DGIdb
PHA-793887 ? unclear Mechanistic DGIdb
RONICICLIB ↓ inhibits Mechanistic DGIdb
MILCICLIB ↓ inhibits Mechanistic DGIdb
R547 ↓ inhibits Mechanistic DGIdb
ASCORBIC ACID ? unclear Mechanistic DGIdb
RGB-286638 ↓ inhibits Mechanistic DGIdb
ANTINEOPLASTIC AGENT ? unclear Mechanistic DGIdb
CGP74514A ↓ inhibits Mechanistic DGIdb
APREMILAST ? unclear Mechanistic DGIdb
CROZBACICLIB ↓ inhibits Mechanistic DGIdb
EBVACICLIB ↓ inhibits Mechanistic DGIdb
VUSTANACICLIB ↓ inhibits Mechanistic DGIdb
CIMPUCICLIB ↓ inhibits Mechanistic DGIdb
PURVALANOL A ↓ inhibits Mechanistic DGIdb
BSJ-03-123 ↓ inhibits Mechanistic DGIdb
CDK1/2/4 INHIBITOR AG-024322 ? unclear Mechanistic DGIdb
TANUXICICLIB ↓ inhibits Mechanistic DGIdb
TIBREMCICLIB ↓ inhibits Mechanistic DGIdb
BIREOCICLIB ↓ inhibits Mechanistic DGIdb
RECOMBINANT TRANSFORMING GROWTH FACTOR ? unclear Mechanistic DGIdb
BSJ-04-132 ↓ inhibits Mechanistic DGIdb
BSJ-03-204 ↓ inhibits Mechanistic DGIdb
CP-10 ↓ inhibits Mechanistic DGIdb
COMPOUND 9B [PMID: 18986805] ↓ inhibits Mechanistic DGIdb
NICOTINE POLACRILEX ? unclear Mechanistic DGIdb
DEXAMETHASONE ? unclear Mechanistic DGIdb
SU9516 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 255 agents ranked by evidence tier.

CDK6

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TRILACICLIB ↓ inhibits Mechanistic DGIdb
INIXACICLIB ↓ inhibits Mechanistic DGIdb
CDK/CRK INHIBITOR ↓ inhibits Mechanistic DGIdb
VUSTANACICLIB ↓ inhibits Mechanistic DGIdb
PALBOCICLIB ↓ inhibits Mechanistic 16.0 nM (IC50) DGIdb
TANUXICICLIB ↓ inhibits Mechanistic DGIdb
FULVESTRANT ? unclear Mechanistic DGIdb
CIMPUCICLIB ↓ inhibits Mechanistic DGIdb
PHA-793887 ↓ inhibits Mechanistic DGIdb
ABEMACICLIB ↓ inhibits Mechanistic DGIdb
TRILACICLIB DIHYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ATIRMOCICLIB ↓ inhibits Mechanistic DGIdb
RIBOCICLIB SUCCINATE ? unclear Mechanistic DGIdb
NARAZACICLIB ↓ inhibits Mechanistic DGIdb
LEROCICLIB ↓ inhibits Mechanistic DGIdb
AZD5438 ↓ inhibits Mechanistic DGIdb
RGB-286638 ↓ inhibits Mechanistic DGIdb
UCN-01 ↓ inhibits Mechanistic DGIdb
BSJ-03-123 ↓ inhibits Mechanistic DGIdb
ULECACICLIB ↓ inhibits Mechanistic DGIdb
BIREOCICLIB ↓ inhibits Mechanistic DGIdb
CROZBACICLIB ↓ inhibits Mechanistic DGIdb
EBVACICLIB ↓ inhibits Mechanistic DGIdb
APREMILAST ? unclear Mechanistic DGIdb
CP-10 ↓ inhibits Mechanistic DGIdb
PRT3645 ↓ inhibits Mechanistic DGIdb
CULMERCICLIB ↓ inhibits Mechanistic DGIdb
TIBREMCICLIB ↓ inhibits Mechanistic DGIdb
ALVOCIDIB ↓ inhibits Mechanistic 80.0 nM (IC50) DGIdb
RIBOCICLIB ↓ inhibits Mechanistic 39.0 nM (IC50) DGIdb
AT-7519 ↓ inhibits Mechanistic DGIdb
BSJ-03-204 ↓ inhibits Mechanistic DGIdb
RONICICLIB ↓ inhibits Mechanistic DGIdb
BSJ-04-132 ↓ inhibits Mechanistic DGIdb
VORUCICLIB ↓ inhibits Mechanistic DGIdb
DALPICICLIB ↓ inhibits Mechanistic DGIdb
AZD-5438 ? unclear Mechanistic Open Targets
FISETIN ↓ inhibits Mechanistic 850.0 nM (IC50) ChEMBL
APIGENIN ↓ inhibits Mechanistic 1700.0 nM (IC50) ChEMBL
KAEMPFEROL ↓ inhibits Mechanistic 22000.0 nM (IC50) ChEMBL

Showing top 40 of 226 agents ranked by evidence tier.

ERBB2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TYRPHOSTIN AG 879 ? unclear Mechanistic DGIdb
TAK-285 ↓ inhibits Mechanistic DGIdb
PERTUZUMAB ↓ inhibits Mechanistic DGIdb
SAPITINIB ↓ inhibits Mechanistic DGIdb
CANERTINIB ↓ inhibits Mechanistic 529.0 nM (IC50) DGIdb
LAPATINIB ↓ inhibits Mechanistic 9.0 nM (IC50) DGIdb
AFATINIB DIMALEATE ↓ inhibits Mechanistic DGIdb
MUBRITINIB ↓ inhibits Mechanistic DGIdb
JNJ-26483327 ↓ inhibits Mechanistic DGIdb
NAKIJIQUINONE I ? unclear Mechanistic DGIdb
AEE788 ↓ inhibits Mechanistic DGIdb
HEMAY-022 ↓ inhibits Mechanistic DGIdb
MM-111 ? unclear Mechanistic DGIdb
NERATINIB ↓ inhibits Mechanistic DGIdb
DACOMITINIB ANHYDROUS ↓ inhibits Mechanistic DGIdb
IXABEPILONE ? unclear Mechanistic DGIdb
DIETHYLSTILBESTROL ? unclear Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
S-222611 ↓ inhibits Mechanistic DGIdb
CP-724714 ? unclear Mechanistic DGIdb
AKT INHIBITOR MK2206 ? unclear Mechanistic DGIdb
ANTINEOPLASTIC AGENT ? unclear Mechanistic DGIdb
TIPIFARNIB ? unclear Mechanistic DGIdb
BMS-599626 ↓ inhibits Mechanistic DGIdb
MIFANERTINIB ↓ inhibits Mechanistic DGIdb
GEFITINIB ↓ inhibits Mechanistic 1604.0 nM (IC50) DGIdb
ADO-TRASTUZUMAB EMTANSINE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
TRASTUZUMAB DUOCARMAZINE ~ modulates Mechanistic DGIdb
POZIOTINIB ↓ inhibits Mechanistic DGIdb
HLX22 ? unclear Mechanistic DGIdb
CURCUMIN ? unclear Mechanistic DGIdb
HSP90 INHIBITOR ? unclear Mechanistic DGIdb
TUCATINIB ↓ inhibits Mechanistic DGIdb
TRASTUZUMAB ↓ inhibits Mechanistic DGIdb
EPIGALLOCATECHIN GALLATE ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
FAM-TRASTUZUMAB DERUXTECAN-NXKI ? unclear Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
TRASTUZUMAB EMTANSINE ~ modulates Mechanistic DGIdb

Showing top 40 of 336 agents ranked by evidence tier.

ESR1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ESTRONE ↑ activates Mechanistic 480.0 nM (EC50) DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb
ANASTROZOLE ? unclear Mechanistic DGIdb
SIVIFENE ? unclear Mechanistic DGIdb
ARZOXIFENE ~ modulates Mechanistic DGIdb
ENDOXIFEN ↓ inhibits Mechanistic DGIdb
OSPEMIFENE ↓ inhibits Mechanistic DGIdb
RALOXIFEN ? unclear Mechanistic DGIdb
FULVESTRANT ↓ inhibits Mechanistic 6.0 nM (IC50) DGIdb
INAVOLISIB ? unclear Mechanistic DGIdb
TESTOSTERONE PROPIONATE ? unclear Mechanistic DGIdb
PHENYLMERCURIC ACETATE ? unclear Mechanistic DGIdb
ESTRADIOL CYPIONATE ↑ activates Mechanistic DGIdb
ESTROGEN ? unclear Mechanistic DGIdb
METHOXSALEN ? unclear Mechanistic DGIdb
BORIC ACID ? unclear Mechanistic DGIdb
IMLUNESTRANT ↓ inhibits Mechanistic DGIdb
PROTOAPIGENONE ? unclear Mechanistic DGIdb
CLOMIPHENE CITRATE ? unclear Mechanistic DGIdb
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
NERATINIB ? unclear Mechanistic DGIdb
ALACHLOR ? unclear Mechanistic DGIdb
METHAMPHETAMINE ? unclear Mechanistic DGIdb
OCHRATOXIN A ? unclear Mechanistic DGIdb
CETRIMONIUM BROMIDE ? unclear Mechanistic DGIdb
EXEMESTANE ? unclear Mechanistic DGIdb
GW7647 ? unclear Mechanistic DGIdb
NORGESTREL ? unclear Mechanistic DGIdb
AMCENESTRANT ↓ inhibits Mechanistic DGIdb
LETROZOLE ? unclear Mechanistic DGIdb
PROGESTERONE ? unclear Mechanistic DGIdb
DIETHYLSTILBESTROL ↑ activates Mechanistic 12.0 nM (EC50) DGIdb
ESTRIOL ↑ activates Mechanistic DGIdb
16&ALPHA;-HYDROXYESTRONE ↑ activates Mechanistic DGIdb
BRILANESTRANT ? unclear Mechanistic DGIdb
LEVONORGESTREL ? unclear Mechanistic DGIdb
ACOLBIFENE ? unclear Mechanistic DGIdb
PROPYLPYRAZOLETRIOL ↑ activates Mechanistic DGIdb
ESTRADIOL VALERATE ↑ activates Mechanistic DGIdb
MEGESTROL ? unclear Mechanistic DGIdb

Showing top 40 of 386 agents ranked by evidence tier.

PARP1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIRAPARIB ↓ inhibits Mechanistic DGIdb
VELIPARIB ↓ inhibits Mechanistic DGIdb
4-[3-(1,4-DIAZEPAN-1-YLCARBONYL)-4-FLUOROBENZYL]PHTHALAZIN-1(2H)-ONE ↓ inhibits Mechanistic DGIdb
PAMIPARIB ↓ inhibits Mechanistic DGIdb
OLAPARIB ↓ inhibits Mechanistic DGIdb
COMPOUND 5 [TOMASSI ET AL., 2020] ↓ inhibits Mechanistic DGIdb
COMPOUND 9 [LIN ET AL., 2023] ↓ inhibits Mechanistic DGIdb
INIPARIB ↓ inhibits Mechanistic DGIdb
AZ1366 ↓ inhibits Mechanistic DGIdb
DUAL VEGFR/PARP INHIBITOR 14B ↓ inhibits Mechanistic DGIdb
NIACIN ? unclear Mechanistic DGIdb
2X-121 ↓ inhibits Mechanistic DGIdb
AMELPARIB DIHYDROCHLORIDE DIHYDRATE ↓ inhibits Mechanistic DGIdb
CEP-9722 ? unclear Mechanistic DGIdb
ORAL AZACITIDINE ? unclear Mechanistic DGIdb
RUCAPARIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
AG14361 ↓ inhibits Mechanistic DGIdb
ME0328 ↓ inhibits Mechanistic DGIdb
SARUPARIB ↓ inhibits Mechanistic DGIdb
SENAPARIB ↓ inhibits Mechanistic DGIdb
NIRAPARIB TOSYLATE ? unclear Mechanistic DGIdb
TALAZOPARIB ↓ inhibits Mechanistic DGIdb
PJ34 ↓ inhibits Mechanistic DGIdb
TALAZOPARIB TOSYLATE ↓ inhibits Mechanistic DGIdb
PARP1 INHIBITOR (S)-G9 ↓ inhibits Mechanistic DGIdb
NICARAVEN ? unclear Mechanistic DGIdb
PARP-1/2 INHIBITOR ABT-767 ? unclear Mechanistic DGIdb
INO-1001 ? unclear Mechanistic DGIdb
BGP-15 ? unclear Mechanistic DGIdb
RUCAPARIB ↓ inhibits Mechanistic DGIdb
TRABECTEDIN ? unclear Mechanistic DGIdb
VENADAPARIB ↓ inhibits Mechanistic DGIdb
FLUZOPARIB ↓ inhibits Mechanistic DGIdb
MC2050 ↓ inhibits Mechanistic DGIdb
PARP INHIBITOR E7016 ? unclear Mechanistic DGIdb
LERZEPARIB ↓ inhibits Mechanistic DGIdb
CICLOPIROX ↓ inhibits Mechanistic DGIdb
E-7016 ↓ inhibits Mechanistic DGIdb
RUCAPARIB CAMSYLATE ↓ inhibits Mechanistic DGIdb
PALACAPARIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

PGR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ETHYNODIOL DIACETATE ↑ activates Mechanistic DGIdb
MIFEPRISTONE ↓ inhibits Mechanistic 0.028 nM (IC50) DGIdb
LAPATINIB ? unclear Mechanistic DGIdb
ETONOGESTREL ↑ activates Mechanistic DGIdb
GESTODENE ↑ activates Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
PROGESTERONE ↑ activates Mechanistic 2.9 nM (EC50) DGIdb
NERATINIB ? unclear Mechanistic DGIdb
NORELGESTROMIN ↑ activates Mechanistic DGIdb
ZK112993 ↓ inhibits Mechanistic DGIdb
ASOPRISNIL ↓ inhibits Mechanistic DGIdb
NORGESTIMATE ↑ activates Mechanistic DGIdb
TELAPRISTONE ? unclear Mechanistic DGIdb
CYPROTERONE ACETATE ↑ activates Mechanistic DGIdb
CHLORMADINONE ACETATE ~ modulates Mechanistic DGIdb
TAMOXIFEN ? unclear Mechanistic DGIdb
EXEMESTANE ? unclear Mechanistic DGIdb
PERTUZUMAB ? unclear Mechanistic DGIdb
PROGESTIN ? unclear Mechanistic DGIdb
MEGESTROL ACETATE ↑ activates Mechanistic DGIdb
PROGESTOGEN ? unclear Mechanistic DGIdb
LONAPRISAN ↓ inhibits Mechanistic DGIdb
NORGESTREL ↑ activates Mechanistic DGIdb
NOMEGESTROL ↑ activates Mechanistic DGIdb
MEDROXYPROGESTERONE ACETATE ↑ activates Mechanistic 0.15 nM (EC50) DGIdb
ULIPRISTAL ~ modulates Mechanistic DGIdb
DYDROGESTERONE ↑ activates Mechanistic DGIdb
NORETHYNODREL ↑ activates Mechanistic DGIdb
ERIBULIN ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE/DIENOGEST ? unclear Mechanistic DGIdb
NORETHINDRONE ACETATE ↑ activates Mechanistic DGIdb
PROMEGESTONE ↑ activates Mechanistic DGIdb
CHEMBL:CHEMBL2059711 ? unclear Mechanistic DGIdb
LETROZOLE ? unclear Mechanistic DGIdb
DANAZOL ↑ activates Mechanistic DGIdb
ULIPRISTAL ACETATE ↓ inhibits Mechanistic DGIdb
APR19 ↓ inhibits Mechanistic DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
PF-05019702 ↓ inhibits Mechanistic DGIdb
VILAPRISAN ? unclear Mechanistic DGIdb

Showing top 40 of 158 agents ranked by evidence tier.

PIK3CA

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SURAMIN ? unclear Mechanistic DGIdb
TEMSIROLIMUS ? unclear Mechanistic DGIdb
RIGOSERTIB ↓ inhibits Mechanistic DGIdb
NEOLYMPHOSTIN A ↓ inhibits Mechanistic DGIdb
INAVOLISIB ↓ inhibits Mechanistic DGIdb
RIGOSERTIB SODIUM ? unclear Mechanistic DGIdb
TAK-733 ? unclear Mechanistic DGIdb
APILIMOD DIMESYLATE CAPSULE ? unclear Mechanistic DGIdb
COMPOUND 15A [PMID: 32069401] ↓ inhibits Mechanistic DGIdb
COMPOUND 41 [PMID: 31855425] ↓ inhibits Mechanistic DGIdb
ERDAFITINIB ? unclear Mechanistic DGIdb
RIBOCICLIB ? unclear Mechanistic DGIdb
BRAFV600/PI3K INHIBITOR ASN003 ? unclear Mechanistic DGIdb
GSK2636771 ↓ inhibits Mechanistic DGIdb
ZINC SULFATE ANHYDROUS ? unclear Mechanistic DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb
COPANLISIB ↓ inhibits Mechanistic DGIdb
TANESPIMYCIN ? unclear Mechanistic DGIdb
CAPIVASERTIB ? unclear Mechanistic DGIdb
SAMOTOLISIB ↓ inhibits Mechanistic DGIdb
COPANLISIB HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PAXALISIB ↓ inhibits Mechanistic DGIdb
U0126 ? unclear Mechanistic DGIdb
PILARALISIB ↓ inhibits Mechanistic DGIdb
M-2698 ? unclear Mechanistic DGIdb
GSK2334470 ? unclear Mechanistic DGIdb
BIMIRALISIB ↓ inhibits Mechanistic DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
SONOLISIB ↓ inhibits Mechanistic 88.0 nM (IC50) DGIdb
VULOLISIB ↓ inhibits Mechanistic DGIdb
ALPELISIB ↓ inhibits Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
COMPOUND 27 [PMID: 35834807] ↓ inhibits Mechanistic DGIdb
MILTEFOSINE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
ACALISIB ↓ inhibits Mechanistic DGIdb
GEDATOLISIB ↓ inhibits Mechanistic DGIdb
VS-5584 ↓ inhibits Mechanistic DGIdb
XRD-0394 ↓ inhibits Mechanistic DGIdb
IZORLISIB ? unclear Mechanistic DGIdb

Showing top 40 of 444 agents ranked by evidence tier.

TACSTD2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SACITUZUMAB GOVITECAN ? unclear Mechanistic DGIdb
DATOPOTAMAB DERUXTECAN ~ modulates Mechanistic DGIdb
HIMB1636-MMAE ? unclear Mechanistic DGIdb
SACITUZUMAB TIRUMOTECAN ? unclear Mechanistic DGIdb

TOP2A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FLUOROURACIL ? unclear Mechanistic DGIdb
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
VOSAROXIN ↓ inhibits Mechanistic DGIdb
EPIRUBICIN ? unclear Mechanistic DGIdb
KAEMPFERITRIN ? unclear Mechanistic DGIdb
MAKALUVAMINE E ? unclear Mechanistic DGIdb
ALDOXORUBICIN ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL244268 ? unclear Mechanistic DGIdb
PYRAZOLOACRIDINE ? unclear Mechanistic DGIdb
ACRIDINE CARBOXAMIDE ? unclear Mechanistic DGIdb
BETULIN ? unclear Mechanistic 38600.0 nM (IC50) DGIdb
CHEMBL:CHEMBL596082 ? unclear Mechanistic DGIdb
LOMEFLOXACIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1080077 ? unclear Mechanistic DGIdb
DOXORUBICIN-MAGNETIC TARGETED CARRIER COMPLEX ? unclear Mechanistic DGIdb
GENISTEIN ? unclear Mechanistic DGIdb
ROSOXACIN ? unclear Mechanistic DGIdb
DOXORUBICIN-HPMA CONJUGATE ? unclear Mechanistic DGIdb
PODOFILOX ? unclear Mechanistic DGIdb
MITOXANTRONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PIXANTRONE ? unclear Mechanistic DGIdb
TRICITRINOL B ? unclear Mechanistic DGIdb
FRANGULIN B ? unclear Mechanistic DGIdb
FLUOROQUINOLONE ANTIBIOTIC ? unclear Mechanistic DGIdb
LYCOBETAINE ? unclear Mechanistic DGIdb
MAKALUVAMINE C TFA SALT ? unclear Mechanistic DGIdb
TAS-103 ? unclear Mechanistic DGIdb
AMSACRINE ↓ inhibits Mechanistic 9940.0 nM (IC50) DGIdb
QUERCETIN ? unclear Mechanistic DGIdb
C-1311 ↓ inhibits Mechanistic DGIdb
ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC ? unclear Mechanistic DGIdb
DAUNORUBICIN LIPOSOMAL ↓ inhibits Mechanistic DGIdb
IDARUBICIN ? unclear Mechanistic DGIdb
OLEANDEROLIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL594259 ? unclear Mechanistic DGIdb
NEMORUBICIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL594153 ? unclear Mechanistic DGIdb
DANIQUIDONE ? unclear Mechanistic DGIdb
ELSAMITRUCIN ? unclear Mechanistic DGIdb
VALRUBICIN ? unclear Mechanistic DGIdb

Showing top 40 of 289 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Breast Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer Active Not Recruiting
NCT04134598 Phase: 3 Started: 2021-02-08

Rationale and relevance for patients and the scientific community. In low risk early stage patients ≥70 years, exclusive radiation therapy (RT) approach might be superior in terms of Health-Related Quality of Life (HRQoL), when compared to exclusive endocrine therapy (ET) following breast-conserving...

A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer. Recruiting
NCT07900516 Phase: 2 Started: 2026-08-01

To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy.

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Recruiting
NCT07391774 Phase: 3 Started: 2026-08-10

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth ...

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer Completed
NCT03025035 Phase: 2 Started: 2017-09-10

This trial will evaluate the use of immunotherapy and PARP inhibition in a population with incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) in combination with Olaparib (PA...

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs Recruiting
NCT06908928 Phase: 1 Started: 2025-08-11

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations Recruiting
NCT07109726 Phase: 1/2 Started: 2025-09-23

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Recruiting
NCT06324357 Phase: 1/2 Started: 2024-06-28

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suit...

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Recruiting
NCT06058377 Phase: 3 Started: 2023-11-27

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies,...

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors Active Not Recruiting
NCT06188520 Phase: 1/2 Started: 2023-12-05

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Active Not Recruiting
NCT06144944 Phase: 3 Started: 2024-01-17

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative) high-risk early breast cancer

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer Recruiting
NCT06891833 Phase: 2/3 Started: 2025-06-05

This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controll...

Pucotenlimab and Anlotinib in Combination With Chemotherapy Recruiting
NCT07896668 Phase: 2 Started: 2025-09-01

A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer. Patients will receive neoadjuvant therapy with pucotenlimab, anlotinib, and nab-pac...

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy Recruiting
NCT05646862 Phase: 3 Started: 2023-06-07

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3...

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases Recruiting
NCT07134153 Phase: 1/2 Started: 2025-05-12

Multiple trials confirm systemic T-DXd efficacy in HER2+ breast cancer with leptomeningeal/brain metastases, yet median LM survival remains 3-4 months, highlighting unmet needs. While systemic therapies improve survival, intracranial disease control remains limited due to poor BBB penetration. Precl...

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer Recruiting
NCT07054190 Phase: 2 Started: 2025-09-09

This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).

Agents Found By Disease-Level Search

Searched directly from “Breast Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 13-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

44 agents shown (approved or with trial evidence) — 28 not found by the gene-target search above.

DocetaxelNOT in gene-target list

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00391092 NCT01779206 NCT00003565

CyclophosphamideNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05269381 NCT01779206 NCT02276300

Fulvestrant

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT03344536 NCT03691493 NCT03280563

Pembrolizumab

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02432963 NCT05269381 NCT07341867

Epirubicin

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00193206 NCT01779206

SargramostimNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05269381 NCT02276300

Exemestane

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03691493 NCT03280563

Tamoxifen

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03691493 NCT03280563

Bevacizumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT06307249 NCT03280563

adjuvant therapyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00667121 NCT00054301

Abemaciclib

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05095207 NCT03280563

PaclitaxelNOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01779206 NCT07341867

carboplatin

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00005963 NCT07341867

bevacizumab [Avastin]NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00391092

HerceptinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00391092

ICG-SG incubation solutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05708144

Modified Vaccinia Virus Ankara Vaccine Expressing p53NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02432963

Gemcitabine

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00193206

Albumin-bound PaclitaxelNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00193206

MBCT-SNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04472104

SexEdNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04472104

TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07601178

RuxolitinibNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02066532

Trastuzumab

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02066532

NIR-II probe (i.e ICG-CK) incubation solutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07154563

ZoladexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01712893

Tailored reminder letterNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07472036

Gefitinib

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00357734

ChlorhexidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02479347

Povidone-IodineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02479347

Neoantigen Peptide VaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

Computed TomographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

Debio 1347NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03344536

AprepitantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01298193

Anastrozole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03691493

Letrozole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03691493

Palbociclib

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03691493

SNPNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

Palbociclib 125mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06307249

citalopram hydrobromideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00667121

escitalopram oxalateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00667121

gabapentinNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00667121

sertraline hydrochloride

· 1 trial · source: ClinicalTrials.gov
NCT00667121

tamoxifen citrate

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00667121

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.